Navigation Links
Heptares to Moderate Panel on Rare Diseases at BBC New York CEO Meeting (13-14 February)
Date:2/8/2013

WELWYN GARDEN CITY, England and BOSTON, February 8, 2013 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery company, announces that its President, Dan Grau , will attend the Boston Biotech Conference New York CEO Meeting taking place on 13-14 February at Apella in New York City, NY, USA, at which he will moderate a panel on Rare Diseases (3:30pm EST, 14 February).

For a full list of events at which Heptares will be present, please visit http://www.heptares.com

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, AstraZeneca, MedImmune, Takeda and Cubist, and we are backed by MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com.


'/>"/>
SOURCE Heptares Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
2. Heptares Solves First Family B GPCR Structure
3. Heptares to Present at BIO-Europe 2012
4. Ali Velshi To Moderate The Food Dialogues (SM): New York On Nov. 15
5. Lucintel Estimates Moderate Growth for Global Pulp and Paper Chemical Industry during 2012-2017
6. Urologists Outraged over Government Panels Recommendation to Stop Life-Saving Prostate Cancer Testing
7. OBN Adds World Class Pharma and VC Figures to its Thematic Advisory Panels
8. NSF awards $450,000 to UNH, Conductive Compounds Inc. for solar panel innovation
9. WaferGens MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center
10. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
11. Researchers Identify New Regulator in Allergic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 18, 2017 The global ... USD 92.9 billion by 2025, according to a ... industry has been adaptive of the function of ... as 2002. Among the services outsourced, clinical trial ... instance, Johnson & Johnson was the first pharmaceutical ...
(Date:1/18/2017)... 2017 According to a new market research report "In ... Disease), & End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global ... 739.9 Million by 2021 from USD 557.1 Million in 2016, growing at a ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics and Sports ... A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, 2017 at Long ... an anterior cervical discectomy and fusion on a 42 year old female who ...
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev customers ... Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers including ... issues such as trial performance metrics, patient enrollment diversity, protocol optimization, and global ...
Breaking Biology Technology:
(Date:12/16/2016)... Research and Markets has announced the addition of the ... report to their offering. ... The biometric vehicle access system market, in terms of ... 2016 to 2021. The market is estimated to be USD 442.7 ... 2021. The growth of the biometric vehicle access system market is ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
(Date:12/15/2016)... AUBURN HILLS, Mich. , Dec. 15, 2016 /PRNewswire/ ... simply unlocking car doors or starting the engine. Continental ... 2017 in Las Vegas . Through ... PASE (Passive Start and Entry) and biometric elements, the ... the field of vehicle personalization and authentication. ...
Breaking Biology News(10 mins):